Kings Arms Yard VCT PLC: Interim Management Statement

Kings Arms Yard VCT PLC Interim Management Statement
LEI Code 213800DK8H27QY3J5R45
I am pleased to present Kings Arms Yard VCT PLC’s (the “Company”) interim management statement for the period from 1 July 2020 to 30 September 2020.
Performance and dividends
The Company’s unaudited net asset value (NAV) as at 30 September 2020 was £77.58 million or 20.71 pence per share (excluding treasury shares), an increase of 0.41 pence per share (2.0 per cent.) since 30 June 2020.
After accounting for the dividend paid of 0.51 pence per share on 30 October 2020 to shareholders on the register on 2 October 2020, the NAV is 20.20 pence per share.Share buy-backsDuring the period from 1 July 2020 to 30 September 2020, the Company purchased 1,705,566 shares for £331,000 at an average price of 19.29 pence per share. All of the shares are to be held in treasury.It remains the Board’s policy to buy back shares in the market, subject to the overall constraint that such purchases are in the Company’s interest, including the maintenance of sufficient resources for investment in existing and new portfolio companies and the continued payment of dividends to shareholders. The level of share buybacks for the sixth month period to 31 December 2020 will be limited to £1 million.It is the Board’s intention for such buy-backs to be at around a 5 per cent. discount to net asset value, so far as market conditions and liquidity permit.PortfolioThe following investments have been made during the period from 1 July 2020 to 30 September 2020:
During the period from 1 July 2020 to 30 September 2020 contracts were exchanged for the sale of Perpetuum Limited, subject to regulatory approval.
Top ten holdings as at 30 September 2020:A full breakdown of the Company’s portfolio can be found on the Company’s webpage on the Manager’s website at, by following the ‘Portfolio of Investments’ link under the ‘Fund reports’ section.Material events and transactions after the period end After the period end, the Company undertook the following investment transactions:Proceeds of £419,000 received from the sale of Clear Review Limited on a cost of £203,000;Investment of £418,000 in a new portfolio company, Seldon Technologies Limited, a software company that enables enterprises to deploy Machine Learning models in production;Investment of £152,000 in a new portfolio company, uMedeor Limited (T/A uMed), a middleware technology platform that enables life science organisations to conduct medical research programmes;Investment of £123,000 in an existing portfolio company, Limitless Technology Limited, a provider of a customer service platform powered by the crowd and machine learning technology; andInvestment of £84,000 in an existing portfolio company, Arecor Limited, which develops biopharmaceuticals through the application of a formulation technology platform.There have been no further significant events or transactions that the Board is aware of which would have a material impact on the financial position of the Company between 1 October 2020 and 10 November 2020.Further information
The Company continues to offer a Dividend Reinvestment Scheme to existing shareholders.  Details of this scheme can be found at
Further information regarding historic and current financial performance and other useful shareholder information can be found on the Company’s webpage on the Manager’s website under Field, Chairman
10 November 2020
For further information please contact:
Albion Capital Group LLP – Tel: 020 7601 1850


Please follow and like us: